2022
DOI: 10.1016/j.freeradbiomed.2022.06.230
|View full text |Cite
|
Sign up to set email alerts
|

The role of cycloastragenol at the intersection of NRF2/ARE, telomerase, and proteasome activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 87 publications
0
3
0
Order By: Relevance
“…1999 ) and telomerase-related genes ( Ahmad et al. 2016 ; Yilmaz et al. 2022 and references therein).…”
Section: Discussionmentioning
confidence: 99%
“…1999 ) and telomerase-related genes ( Ahmad et al. 2016 ; Yilmaz et al. 2022 and references therein).…”
Section: Discussionmentioning
confidence: 99%
“…Cycloastragenol is the only telomerase activator that has antiaging effects by increasing telomerase levels to delay telomere shortening (116,117). Astragaloside IV (AG-IV) has a variety of drug properties, such as anti-inflammatory, anti-IR and neuroprotective effects (118)(119)(120).…”
Section: Drug Therapy Of Diabetic Iddmentioning
confidence: 99%
“…The paper by Yao et al [22] uses panaxatriol saponin to ameliorate myocardial infarction-induced cardiac fibrosis in a NRF2/KEAP1 dependent manner. Yilmaz et al [23] report that cycloastragenol activates telomerase in a NRF2-dependent manner, suggesting an anti-ageing effect. Finally, Moreno et al [24], show that a biotinylated derivative of an acetylenic tricyclic bis(cyanoenone), but not its parent compound, exhibits bifunctional effects, activating NRF2 and inhibiting BACH1, a transcriptional repressor of a subset of NRF2-target genes.…”
mentioning
confidence: 99%